Age dependent phosphorylation and deregulation of p53 in human vestibular schwannomas

Molecular Carcinogenesis

Volumn 45, Issue 1, 2006, Pages 38-46

  Dayalan, Antony H P P ^a   Jothi, Mathivanan ^a   Keshava, Rohini ^a   Thomas, Remy ^a   Gope, Mohan L ^b   Doddaballapur, Subbakrishna K ^a   Somanna, Sampath ^a   Prabaraj, Shanti S ^a   Ashwathnarayanarao, Chandramouli B ^a   Gope, Rajalakshmi ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b City College   (India)

Author keywords

Human vestibular schwannomas; LOH; p53 mrna; p53 protein; Ser 392 phosphorylation

Indexed keywords

MESSENGER RNA; PROTEIN P53; SERINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CARCINOGENESIS; CASE REPORT; CORRELATION ANALYSIS; FEMALE; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; MALE; NEURILEMOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VESTIBULAR DISORDER; VESTIBULAR SCHWANNOMA;

ADOLESCENT; ADULT; AGED; AGING; BLOTTING, WESTERN; CELL LINE; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEUROMA, ACOUSTIC; PHOSPHORYLATION; RNA, MESSENGER; SERINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 31044432520     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20150     Document Type: Article

References (46)

1. Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 1988;318:684-688.
2. Baldwin D, King TT, Chevretton E, Morrison AW. Bilateral cerebellopontine angle tumors in neurofibromatosis type 2. J Neurosurg 1991;74:910-915.
3. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515-521.
4. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel meosine-, ezrin-, radixin-like gene is candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800.
5. Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science 1987;238:193-197.
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
7. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-708.
8. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995;83:237-245.
9. Yap DB, Hsieh JK, Zhong S, et al. Ser 392 phosphorylation regulates the oncogenic function of mutant p53. Cancer Res 2004;64:4749-4754.
10. Kim H, Kwak NJ, Lee JY, et al. Merlin neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 2004;279:7812-7818.
11. Gope R, Christensen MA, Thorson A, et al. Increased expression of the retinoblastoma gene in human colorectal carcinomas relative to normal colonic mucosa. J Natl Cancer Inst 1990;82:310-314.
12. Gope ML, Chun M, Gope R. Comparative study of the expression of Rb and p53 genes in human colorectal cancers, colon carcinoma cell lines and synchronized human fibroblasts. Mol Cell Biochem 1991;107:55-63.
13. Thomas R, Antony Herald Prabhu PD, Mathivanan J, et al. Altered structure and expression of RB1 gene and increased phosphorylation of pRb in human vestibular schwannomas. Mol Cell Biochem 2005;271:113-121.
14. Lamb P, Crawford L. Characterization of the human p53 gene. Mol Cell Biol 1986;6:1379-1385.
15. Singh S, Simon M, Meybohm I, et al. Human breast cancer: Frequent p53 allele loss and protein overexpression. Hum Genet 1993;90:635-640.
16. Gope R, Gope ML. Abundance and state of phosphorylation of the retinoblastoma susceptibility gene product in human colon cancer. Mol Cell Biochem 1992;110:123-133.
17. Fitch ME, Cross IV, Turner SJ, et al. The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. DNA Repair (Amst) 2003;2:819-826.
18. Stoyanova R, Clapper ML, Bellacosa A, et al. Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther 2004;3:1313-1321.
19. Koshiji M, Yonekura Y, Saito T, Sakaida N, Uemura Y, Yoshioka K. Genetic alterations in normal epithelium of colorectal cancer patients may be a useful indicator for subsequent metachronous tumor development. Ann Surg Oncol 2002;9:580-586.
20. Malins DC, Gilman NK, Green VM, et al. Metastatic cancer DNA phenotype identified in normal tissues surrounding metastasizing prostate carcinomas. Proc Natl Acad Sci USA 2004;101:11428-11431.
21. Monoh K, Ishikawa K, Yasui N, Mineura K, Andoh H, Togawa K. p53 tumor suppressor gene in acoustic neuromas. Acta Otolaryngol Suppl 1998;537:11-15.
22. Tamada H, Suzuki Y, Tamura G. Analysis of loss of heterozygosity (LOH) at the p53 and Rb suppressor genes in urinary bladder carcinoma. Nippon Hinyokika Gakkai Zasshi 1994;85:722-730.
23. Yamaguchi K, Sugano K, Fukayama N, et al. Polymerase chain reaction-based approaches for detection of allelic loss in the p53 tumor suppressor gene in colon neoplasms. Am J Gastroenterol 1997;92:307-312.
24. Jin W, Xu X, Yang T, Hua Z. p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas. Chin Med J (Engl) 2000;113:662-666.
25. Matsushima AY, Cesarman E, Chadburn A, Knowles DM. Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 1994;144:573-584.
26. Jung HL, Wang KC, Kim SK, et al. Loss of heterozygosity analysis of chromosome 17p13.1-13.3 and its correlation with clinical outcome in medulloblastomas. J Neurooncol 2004;67:41-46.
27. Miyamoto H, Shuin T, Ikeda I, Hosaka M, Kubota Y. Loss of heterozygosity at the p53, RB, DCC and APC tumor suppressor gene loci in human bladder cancer. J Urol 1996;155:1444-1447.
28. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 1992;52:674-679.
29. Hsieh LL, Huang TH, Chen IH, et al. p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. Br J Cancer 2005:92:30-35.
30. Rasheed BK, McLendon RE, Herndon JE, et al. Alterations of the TP53 gene in human gliomas. Cancer Res 1994;54:1324-1330.
31. Semczuk A, Marzec B, Postawski K, et al. Allelic losses at the p53 gene in primary human endometrial carcinomas. Eur J Biochem 2003;1:P1.1-P35.
32. Roy SW, Gilbert W. The pattern of intron loss. Proc Natl Acad Sci USA 2005;102:713-718.
33. Chen YH, Li CD, Yap EP, McGee JO. Detection of loss of heterozygosity of p53 gene in paraffin-embedded breast cancers by non-isotopic PCR-SSCP. J Pathol 1995;177:129-134.
34. Bosari S, Viale G, Roncalli M, et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 1995;147:790-798.
35. O'Farrell TJ, Ghosh P, Dobashi N, Sasaki CY, Longo DL. Comparison of the effect of mutant and wild-type p53 on global gene expression. Cancer Res 2004;64:8199-8207.
36. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
37. Tuck SP, Crawford L Overexpression of normal human p53 in established fibroblasts leads to their tumorigenic conversion. Oncogene Res 1989;4:81-96.
38. Cesarman E, Inghirami G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 1993;143:845-856.
39. Vojtesek B, Lane DP. Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci 1993;105:607-612.
40. Wang YC, Lin RK, Tan YH, Chen JT, Chen CY, Wang YC. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: An alternative pathway to non-small-cell lung cancer. J Clin Oncol 2005;23:154-164.
41. Flejou JF, Potet F, Muzeau F, Le Pelletier F, Fekete F, Henin D. Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J Clin Pathol 1993;46:330-333.
42. Halazonetis TD, Davis LJ, Kandil AN. Wild-type p53 adopts a 'mutant'-like conformation when bound to DNA. EMBO J 1993;12:1021-1028.
43. Chen D, Padiernos E, Ding F, Lossos IS, Lopez CD. Apoptosis-stimulating protein p53-2 (ASPP2/53BP2L) is an E2F target gene. Cell Death Differ 2005;12:358-368.
44. Yamauchi M, Suzuki K, Kodama S, Watanabe M. Abnormal stability of wild-type p53 protein in a human lung carcinoma cell line. Biochem Biophys Res Commun 2005;330:483-488.
45. Ogawa K, Kanzaki J, Ogawa S, Yamamoto M, Ikeda S, Shiobara R. The growth rate of acoustic neuromas. Acta Otolaryngol Suppl 1991;487:157-163.
46. Baser ME, Makariou EV, Parry DM. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2. J Neurosurg 2002;96:217-222.